RecruitingNot ApplicableNCT06666790

DermaSensor Postmarket Surveillance Study


Sponsor

DermaSensor, Inc.

Enrollment

396 participants

Start Date

Oct 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.


Eligibility

Min Age: 40 Years

Inclusion Criteria3

  • Men or women of any ethnic group aged 40 and older
  • Primary skin lesion suspicious for melanoma
  • Patient is willing and able to read, understand, and sign the informed consent form (ICF)

Exclusion Criteria14

  • Lesion is not accessible to the DermaSensor device Handheld Unit and tip (e.g., inside ears, under nails, etc.)
  • Lesion is on areas of psoriasis, eczema, acne, or similar inflammatory skin conditions that may impede appropriate DermaSensor device tip placement on the lesion.
  • Lesion is greater than 15mm in diameter at the widest point.
  • Lesion has a targeted area less than 2.5mm in diameter where the DermaSensor device tip cannot be placed entirely within the border of the targeted area of the lesion.
  • Lesion has no contiguous area of at least 2.5mm due to ulceration, erosion or liquid discharge (e.g., blood).
  • Lesion is covered by a crust or scale, and lesion surface cannot be cleared of crust or scale such that there is a contiguous area of at least 2.5mm of cleared intact skin that is free of any crust, ulceration, erosion or liquid discharge (e.g., blood).
  • Lesion is obstructed by foreign matter that cannot be non-invasively removed (e.g., tattoo, splinter, etc.)
  • Lesion is not completely cleared of (i.e., free of any remaining residue) dermoscopy oils, makeup, sunscreen, other topical solutions or powders, markings, and staining treatments (e.g., iodine).
  • Lesion is located on acral skin (e.g., sole or palms).
  • Lesion is located within 10mm of the eye.
  • Lesion is on or adjacent to scars, areas previously biopsied, or areas subjected to any past surgical intervention.
  • Lesion is located on mucosal surfaces (e.g. genitals, lips).
  • Lesion is located in an area with acute sunburn.
  • Dementia or other neurologic, physical or psychological limitation that would prevent the patient from signing informed consent and/or completing any required follow-up visits

Interventions

DEVICEScan with elastic scattering spectroscopy device to assess risk of malignancy

Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology


Locations(2)

Velocity

New Smyrna Beach, Florida, United States

West Clinical Research

Morehead City, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06666790


Related Trials